Senior Postdoctoral Researcher in Immuno-Oncology - BJ0921
84, rue Val Fleuri, Luxembourg L-1526, Luxembourg
Background and Research environment:
Cancer immunotherapy is a rapidly evolving field for cancer treatment. TIME group is conducting oncology research at the forefront of translating basic research knowledge in the field of immuno-oncology into clinical applications. The strategic priority of TIME group relies on discovering and defining druggable gene targets in tumour cells and key pathways in the tumour microenvironment able to reprogram “cold immune desert tumours” into “hot inflamed immune infiltrated tumours”. The translational aspect of TIME research activities depends on establishing collaboration with pharma companies to develop innovative highly selective drugs inhibiting such targets. The ultimate aim of the TIME group is to meet the urgent clinical needs and take full advantage of the impressive therapeutic value of immunotherapies by extending their use to non-responder cancer patients.
Immune checkpoint blockade (ICB)-based cancer immunotherapy is a game-changer in terms of overall survival and cancer patient’s life quality. Despite the encouraging clinical responses in few patients, the majority of them have a short-term or no survival benefit with severe side effects. The future of immuno-oncology drug development is positioned in combination immunotherapies involving standard cancer therapies rationally combined with ICB’s to boost their efficacy and reduce resistance. This position relies on understanding the molecular mechanism of action of a groundbreaking combination of ICB’s and innovative drugs targeting key pathways involved in impairing the anti-tumour immunity. This innovation-driven collaborative project between academic research group at LIH and Pharma Company will undoubtedly contribute to improving the survival benefit of ICB-based cancer immunotherapy in non-responder patients.
Lequeux et al., Oncogene 2021. https://pubmed.ncbi.nlm.nih.gov/34155342/
Noman et al., Science Advances 2020. https://pubmed.ncbi.nlm.nih.gov/32494661/
Mgrditchian et al., PNAS 2017 https://pubmed.ncbi.nlm.nih.gov/29078276/
Baginska et al., PNAS 2013 https://pubmed.ncbi.nlm.nih.gov/24101526/
Noman, Janji et al., Cancer Res. 2011 https://pubmed.ncbi.nlm.nih.gov/21810913/
KEY SKILLS, EXPERIENCE AND QUALIFICATIONS
- PhD in Cellular and Molecular Biology or Oncology with strong expertise in cancer immunology.
- Strong experience in: Animal experimentation (animal experimentation diploma is mandatory); Immune phenotyping using CyTOF; scRNAseq; Handling large sets of bioinformatics data; Molecular biology and Cell imaging techniques.
- Independent and self-motivated person, scientific creativity and originality, strong team spirit and collaborative capacity, excellent time management, rigour, perseverance, strong writing skills.
- Fluency in English is mandatory.
In addition to the attractive salary, the successful candidate will join a highly dynamic research environment and get access to several core facilities and relevant state-of-the-art technologies. S/he will benefit from an active seminar program, international conference attendances and opportunities to collaborate with biotech and pharma companies.
Dr Bassam Janji (PhD, HDR)
Luxembourg Institute of Health – Department of Oncology
84 Val Fleuri, L-1526 Luxembourg City. LUXEMBOURG
- Contract type: 2-year fixed-term contract (renewable)
- Work hours: Full time- 40h/week
- Location: Luxembourg
- Start date: January 2022
- Ref: VD/SPDR0921/BJ/TIME